Huangming Hong

Apr 2, 2024 | genomemedicine.biomedcentral.com | Zegeng Chen |He Huang |Huangming Hong |Huageng Huang |Huawei Weng |Le Yu | +6 more

The clinical features of all 163 enrolled patients were examined and a side-by-side comparison among different cohorts was performed. Majority of patients (97.1%, 136 out of 140 patients whose treatment information is accessible) received first-line asparaginase-based chemotherapy. The NODE and ICGC cohorts are mostly comprised of primary patients, whereas the NKT_project and EGA cohorts contain more relapsed/refractory patients (Additional file 2: Table S2).

Feb 20, 2024 | nature.com | Zegeng Chen |Huilai Zhang |Zhiming Li |Huangming Hong

AbstractNatural killer/T-cell lymphoma (NKTCL) is a highly heterogeneous disease with a poor prognosis. However, the genomic characteristics and proper treatment strategies for non-upper aerodigestive tract NKTCL (NUAT-NKTCL), a rare subtype of NKTCL, remain largely unexplored. In this study, 1589 patients newly diagnosed with NKTCL at 14 hospitals were assessed, 196 (12.3%) of whom had NUAT-NKTCL with adverse clinical characteristics and an inferior prognosis.